| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 9 | 40 | -0,50 % | ||
| VESTAS WIND SYSTEMS | 9 | 9 | +1,91 % | ||
| GENMAB | 5 | - | -2,65 % | ||
| JYSKE BANK | 3 | 3 | +0,09 % | ||
| DANSKE BANK | 1 | 10 | +0,43 % | ||
| PANDORA | 1 | 1 | +0,13 % | ||
| ISS | 1 | 1 | +0,63 % | ||
| AP MOELLER-MAERSK | - | 23 | +0,39 % | ||
| ORSTED | - | 17 | +1,18 % | ||
| BAVARIAN NORDIC | - | 7 | +1,34 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:47 | Genmab-Aktie fällt nach Einstellung der Acasunlimab-Entwicklung | 3 | Investing.com Deutsch | ||
| 17:30 | Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat | 12 | Benzinga.com | ||
| 16:42 | Novo Nordisk's Wegovy Pill Wins U.S. Approval | 20 | Contract Pharma | ||
| 16:38 | Eilmeldung am Abend: NOVO NORDISK A/S kippt - Chance jetzt? | 11 | Maximilian Berger | ||
| 16:33 | Vestas lands 390 MW offshore wind contract in South Korea | 3 | PortNews | ||
| 16:18 | Genmab ends development of late-stage oncology asset acasunlimab | 4 | Seeking Alpha | ||
| 15:24 | Genmab To Discontinue Clinical Development Of Acasunlimab To Focus On Priority Programs | 197 | AFX News | BRUSSELS (dpa-AFX) - Genmab A/S (GMAB), Monday announced the decision to discontinue further clinical development of acasunlimab to focus on programs with the highest potential impact, such... ► Artikel lesen | |
| 14:58 | Vestas bags 188MW Irish order | 1 | reNews | ||
| 14:51 | Vestas gibt Aufträge in Irland über insgesamt 188 MW bekannt | 8 | Windkraft-Journal | ||
| 14:48 | Pandora A/S: Transactions in connection with share buyback programme | 6 | GlobeNewswire (USA) | ||
| 14:18 | Genmab A/S: Genmab Portfolio Prioritization Update | 184 | Business Wire | Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher-impact opportunities across Genmab's... ► Artikel lesen | |
| 14:09 | Novo Nordisk: Kurssprung nach Weihnachten - oder nur wieder ein Fehlsignal? | 408 | BÖRSE ONLINE | Die FDA gibt kurz vor Weihnachten grünes Licht für die erste orale Version von Wegovy - und Novo Nordisk überraschte die Anleger mit einem Kurssprung. Chart, Konkurrenz und Analysten zeigen nun ein... ► Artikel lesen | |
| 14:09 | VESTAS WIND SYSTEMS A/S: Vestas announces orders in Ireland for a total of 188 MW | 7 | Cision News | ||
| 13:28 | GENMAB A/S - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 13:05 | Vestas Receives Order for South Korean Offshore Wind Project | 2 | OffshoreWIND.biz | ||
| 12:41 | Vestas Books First South Korean Offshore Wind Order | 4 | Offshore Engineer | ||
| 12:26 | Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK | 57 | Insider Monkey | ||
| 11:21 | Vestas sichert sich 390-MW-Offshore-Auftrag in Südkorea | 6 | Windkraft-Journal | ||
| 11:09 | VESTAS WIND SYSTEMS A/S: Vestas secures 390 MW offshore order in South Korea | 4 | Cision News | ||
| 10:59 | Vestas lands 390MW Korean offshore wind order | 4 | reNews |